Table 2.
Laboratory Parameters
| All subjects (n=31) |
Placebo (n=12) |
Active (n=14) |
|||
|---|---|---|---|---|---|
| Baseline | Baseline | Post | Baseline | Post | |
| WBC (×103/µL) | 6.5±0.4 | 6.9±0.7 | 7.2±0.7 | 6.1±0.5 | 6.7±0.6 |
| Hematocrit (%) | 38.6±0.8 | 38.3±1.4 | 38.9±1.3 | 39.1±1.1 | 39.1±1.2 |
| Platelet (×103/µL) | 206.8±9.7 | 205±15.6 | 212.8±17 | 209.3±14.3 | 188±10 |
| Sodium (mEq/L) | 137.9±0.4 | 138.3±0.7 | 138.7±0.7 | 137.5±0.5 | 136.8±1 |
| Potassium (mEq/L) | 4.5±0.08 | 4.5±0.2 | 4.2±0.1 | 4.4±0.06 | 4.2±0.1 |
| Blood urea nitrogen (mg/dL) | 19.9±1.2 | 19±1.9 | 20.5±2.5 | 19.4±1.5 | 24.5±2.8 |
| Creatinine (mg/dL) | 1.1±0.05 | 1.1±0.07 | 1.2±0.1 | 1.1±0.06 | 1.1±0.09 |
| Albumin (mg/dL) | 4.4±0.07 | 4.4±0.1 | 4.4±0.1 | 4.4±0.1 | 4.4±0.09 |
| Total bilirubin (mg/dL) | 0.75±0.07 | 0.73±0.09 | 0.78±0.1 | 0.77±0.1 | 0.71±0.1 |
| Aspartate aminotransferase (U/L) | 23.5±1.4 | 23.1±2.5 | 23.3±2.6 | 23.1±1.7 | 23.2±3.5 |
| Alanine transaminase (U/L) | 22±1.7 | 19.8±1.8 | 20±1.8 | 23.5±2.5 | 21.2±1.5 |
| Cholesterol (mg/dL) | 164.4±8.7 | 164.4±13 | 165.5±12 | 168.6±12 | 170.9±15 |
| HDL (mg/dL) | 43.8±2.3 | 44.5±4.6 | 43.8±3.2 | 43.3±3 | 41.3±3.8 |
| LDL (mg/dL) | 90.9±6.2 | 85.5±9.6 | 84.3±7.5 | 98.3±8 | 100.3±12 |
| Triglycerides (mg/dL) | 184.4±32.9 | 158.8±22 | 186.5±27 | 207.4±57 | 172.3±36 |
| TNFα (pg/mL) | 3.2±0.5 | 3.4±0.6 | 2.5±0.4 | 3.1±0.8 | 3.3±0.5 |
WBC, white blood cell; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNFα, tumor necrosis factor alpha. Post represents 3 months following the intervention. Values expressed at Mean ± SEM